Tarsons Products Limited · NSE:TARSONS
Tarsons Products — Q2 FY2026 Earnings Presentation
29 slides from Tarsons Products's earnings presentation, Nov 13, 2025
Slide 1: Exchange filing cover letter for investor presentation
An ISO 9001 & ISO 13485 Certified Company Date: November 13, 2025 To, To, BSE Limited (“BSE”), National Stock Exchange of India Limited Corporate Relationship Department, (“NSE”) 2nd Floor, New Trading Ring, “Exchange Plaza”, 5th Floor, P.J. Towers, Dalal Street, Plot No. C/1, G Block, Mumbai – 400
Slide 2: Tarsons Products Limited Investor Presentation November 2025
TARSONS PRODUCTS LIMITED Investor Presentation November 2025 TRUST DELIVERED
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Q2 & H1FY26 Financial & Operational Highlights
Q2 & H1FY26 Financial & Operational Highlights
Slide 5: Q2 & H1FY26 Key Operational Highlights
Q2 & H1FY26 Key Operational Highlights Revenue Mix : Geography Wise Revenue Mix : Geography Wise 35% 32% 34% 32% Standalone Q2FY25 Q2FY26 H1FY25 H1FY26 65% 68% 66% 68% Consolidated 47% 47% 48% 47% Q2FY25 Q2FY26 H1FY25 52% H1FY26 53% 53% 53% Domestic Overseas 4
Slide 6: Q2 & H1FY26 Standalone Financial Highlights
Q2 & H1FY26 Standalone Financial Highlights Revenue (in Rs. crs) EBITDA^ (in Rs. crs) Profit After Tax (in Rs. crs) Cash PAT# (in Rs. crs) +5% +19% -48% +19% 145.0 151.8 48.4 19.4 48.0 40.5 -50% 40.3 flat +11% +7% 12.9 80.1 80.5 26.1 10.1 24.9 26.7 23.5 6.5 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26
Slide 7: Q2 & H1FY26 Consolidated Financial Highlights
Q2 & H1FY26 Consolidated Financial Highlights Revenue (in Rs. crs) EBITDA^ (in Rs. crs) Profit After Tax (in Rs. crs) Cash PAT# (in Rs. crs) +5% +18% -64% +21% 184.0 193.7 52.1 14.3 47.5 -68% 44.0 39.4 +3% +8% 10.3 +6% 99.2 102.3 27.4 24.3 25.8 25.3 5.1 3.3 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26
Slide 8: Bridge between Standalone & Consolidated PAT – H1FY26
Bridge between Standalone & Consolidated PAT – H1FY26 (in Rs. crs) 10.1 -2.9 1.4 5.1 -1.9 -1.6 H1FY26 Interest Income and Interest paid to Amortisation on Nerbe PAT H1FY26 Standalone PAT SBLC Amortisation bank by subsidiary intangible Consolidated PAT eliminated at assets acquired consolidation leve
Slide 9: Management Commentary
Management Commentary Commenting on the performance, Mr. Aryan Sehgal, Promoter and Whole time Director of Tarsons, said: “Consolidated Revenue for H1FY26 stood at ₹193.7 crore, reflecting a growth of 5.2% year-on-year. EBITDA grew by 18.4% YoY to ₹52.1 crore compared to ₹44.0 crore in H1FY25. PAT w
Slide 10: Q2 & H1FY26 Standalone Profit & Loss Statement
Q2 & H1FY26 Standalone Profit & Loss Statement Particulars (in Rs. Crs) Q2FY26 Q2FY25 Y-o-Y H1FY26 H1FY25 Y-o-Y Revenue from Operations 80.5 80.1 0.5% 151.8 145.0 4.7% Cost of Goods Sold 21.9 22.9 42.3 41.0 Gross Profit 58.6 57.2 2.6% 109.5 104.0 5.3% Gross Margin (%) 72.8% 71.4% 150 bps 72.2% 71.7%
Slide 11: Q2 & H1FY26 Consolidated Profit & Loss Statement
Q2 & H1FY26 Consolidated Profit & Loss Statement Particulars (in Rs. Crs) Q2FY26 Q2FY25 YoY H1FY26 H1FY25 YoY Revenue from Operations 102.3 99.2 3.1% 193.7 184.0 5.2% Cost of Goods Sold 33.2 32.6 62.5 60.3 Gross Profit 69.1 66.6 3.7% 131.2 123.7 6.0% Gross Margin (%) 67.5% 67.1% 40 bps 67.7% 67.2% 5
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet Consolidated Consolidated Assets (in Rs. Crs) Equity & Liabilities (in Rs. Crs) Sep-25 Mar-25 Sep-25 Mar-25 Total Equity 626.6 630.2 Non-Current Assets 909.6 837.5 Share Capital 10.6 10.6 Property Plant & Equipment 504.1 455.1 Other Equity 616.0 619.6 CWIP 251.0 232.9 Non-
Slide 13: Abridged Consolidated Cash Flow Statement
Abridged Consolidated Cash Flow Statement Consolidated Particulars (in Rs. Crs) H1FY26 H1FY25 Net Profit Before Tax 8.6 21.2 Adjustments for: Non -Cash Items / Other Investment or Financial Items 46.3 38.8 Operating profit before working capital changes 55.0 60.0 • Net cash from operating Changes in
Slide 14: About Tarsons
TRUST DELIVERED
Slide 15: Tarsons – at a Glance
Tarsons – at a Glance One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments) Products used in laboratories across research organizations, academia institutes, pharm
Slide 16: Our Journey
Our Journey Established Product portfolio Commenced Pioneered the first fully manufacturing facility expansion & adding Established line for PCR production of Pipette robotic clean room expanding into depth in existing products in Jalan Tips, thereby creating a plant for manufacturing production of
Slide 17: Leading Indian Labware Supplier
Leading Indian Labware Supplier Trusted Brand for high quality Expertise in production of a wide range Ability to offer differentiated, user products in the plastic labware of labware products & amongst the friendly, reliable quality & cost-effective market with 40+ years vintage in the top 3 player
Slide 18: Our Competitive Edge
Our Competitive Edge Geographical Presence Brand & Quality Wide geographic reach through a Leading Indian supplier to the life sciences strong sales & distribution sector with strong brand recognition and network high-quality diversified products across varied customer segments. 03 04 State of Art F
Slide 19: Catering to diversified End User Industry
Catering to diversified End User Industry… Measures to strengthen customer relations Academic Institutes National Centre Indian Institute of Rain Forest KIIT Regular Feedback from Customers on quality, & Research for Biological Chemical Research Institute University 1 delivery & cost Sciences Techno
Slide 20: Our State-of-the-art Manufacturing Facilities
Our State-of-the-art Manufacturing Facilities… Key Highlights of the High Precision Manufacturing Process ✓ Vertically integrated manufacturing capabilities with design & development being carried out in-house ✓ Automated manufacturing with use of robotics & other technologies developed in collabora
Slide 21: Widespread Domestic Sales & Distribution network
…with widespread Domestic Sales & Distribution network… Comprehensive Pan-India Distribution Network Long-standing relationships with Distributors North: 17% of FY25 Domestic Sales East: 13% of FY25 Domestic Sales 42 Distributors 42 Distributors West: 29% of FY25 Domestic Sales 23 Distributors South
Slide 22: Huge Underlying Export Market Potential
…with huge underlying Export Market Potential… Huge Export Opportunity Market One of the very few players to have a Global Reach ✓ As of 31st March 2025, the company sold its products to 40+ countries via 45+ distributors Demand for plasticware expected to grow at 10% CAGR for developing ✓ Export op
Slide 23: Wide Range of High-Quality Products
…offering Wide Range of High-Quality Products… Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachable Consumables Reusables Others 55.5% of FY25 40.7% of FY25 3.8% of FY25 Revenues Revenues Revenues • Portfoli
Slide 24: Diversified product portfolio of Plastic Labware: Consumables
…diversified product portfolio of Plastic Labware Centrifuge Sterile Media Pipette Tips Petri Dishes Cryo Vials Storage Vials Serological Pipette Tubes Bottles Consumables (55% of FY25 Sales) • Mostly used in culture Designed for use Disposable pipettes Suited to preparation Used for storage of Perf
Slide 25: Key Business Strategies
Key Business Strategies • Focus on branding & promotion to enhance visibility in the labware industry to increase brand awareness & loyalty • Manufacture New Products in the cell culture & robotic handled consumables and expand Enhance existing & expand into the import dominated markets of these pro
Slide 26: Experienced Board of Director & Managerial Team
Experienced Board of Director & Managerial Team Mr. Ramanathan Subramanian Suresh Prabhala Sanjive Sehgal Non-Executive Director Arun Kumar Chairman & Managing Director Non-Executive Nominee Director • Co-founder & Managing Partner at ADV Partners. • Partner & COO at ADV Partners with 25 • Investmen
Slide 27: Contribution towards Environmental, Social & Governance
Contribution towards Environmental, Social & Governance Clean room conditions eliminates all chances of NO litigations faced for pollution or contamination Use of Medical Grade degradation of environment over the Plastics. Products are designed to past five years Productivity optimisation with use o
Slide 28: Key Takeaways
Key Takeaways Leading Indian manufacturer of Financial profile with Historical labware with an established brand strong EBITDA margins & high & focus on high-quality products ROCE Presence in an industry with Highly automated state-of-the-art double-digit growth potential and manufacturing facilitie
Slide 29: Thank You
Thank You Tarsons Products Limited Strategic Growth Advisors Private Limited CIN: L51109WB1983PLC036510 CIN: U74140MH2010PTC204285 Mr. Santosh Agarwal – Chief Financial Officer Mr. Sagar Shroff / Mr. Tanay Shah santosh@tarsons.in sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98205 19303 / +91 98